Counterfeit semaglutide poses a different problem from choosing an online pharmacy: the product in someone’s possession may not be the authentic medicine represented on its label. FDA has reported counterfeit Ozempic injections entering the U.S. drug supply chain, including a December 5, 2025 update involving products labeled with an authentic lot number. Consequently, even a familiar-looking batch number cannot establish authenticity by itself.
An unfamiliar label, unexpected packaging, broken seal, unexplained sourcing or inconsistent device can justify immediate scrutiny. But a consumer cannot reliably authenticate semaglutide from a photograph or one checklist item. The appropriate response to a suspected counterfeit is to stop using that unit, retain the packaging and seek help from the dispensing pharmacist and relevant manufacturer or regulator.
This guide focuses on suspicious products, documented FDA alerts and safe reporting steps. If you are still selecting the seller, use the independent pharmacy license checklist instead; for imported-brand approval questions, use the foreign-product guide.
FDA issued an April 14, 2025 alert involving counterfeit Ozempic 1 mg injection units with specific identifying details and later updated its alert on December 5, 2025 concerning additional suspected products. For the December group, the lot number appeared on authentic product as well, and FDA described a label-layout distinction. These are dated, product-specific warnings, not a permanent test for every Ozempic or Wegovy pack.
Alert details can be updated as investigations proceed. Follow the current FDA notice rather than treating an old image, serial-number pattern or social media post as an exhaustive authentication method.
Use the following observations to organize concerns for a pharmacist. A normal appearance is not proof of authenticity, and a difference may also reflect a legitimate change in packaging or presentation.
For the separate question of whether the seller is licensed, see online dispensing-channel risks.
| What you notice | Why it matters | Who can investigate |
|---|---|---|
| Pack, device or labeling differs | Possible mismatch, tampering or legitimate packaging change | Dispensing pharmacist and manufacturer |
| Unfamiliar source or resale offer | Chain-of-custody uncertainty | Pharmacy and state board |
| Lot/expiration mismatch | May signal mislabeled or suspect product | Manufacturer through pharmacist |
| Shipping or storage damage | Quality concern even for authentic medicine | Dispensing pharmacist |
| New unexpected reaction | Could be clinical or product quality issue | Prescriber immediately; FDA reporting |
| Offer explicitly labeled “no Rx” | Questionable distribution, not proof of counterfeit | State board and FDA |
A counterfeit product falsely represents identity or source. An imported brand may be genuine in its home market yet lack FDA approval for sale in the United States. A compounded preparation is specially prepared under different legal conditions and is not an FDA-approved manufactured brand, even when offered by a licensed facility.
Learn the distinct issues in compounded semaglutide regulations and imported-product status. Treating every nonstandard product as a counterfeit obscures the actual buyer risk.
Do not inject or swallow the suspect product before it has been evaluated. Keep it in its original packaging and retain receipts, dispensing labels, lot and expiration details. Contact the pharmacy using a verified number and explain what does not match; ask for instructions on securing the product for examination.
If a dose was already used and you have significant symptoms, seek prompt medical assistance. Do not attempt to test authenticity by taking another dose, transferring medicine to another container or independently decoding a serial number.
The December 2025 FDA alert expressly noted that a counterfeit label carried a lot number also used on authentic Ozempic. Therefore the mere presence of a named lot does not prove a package is fraudulent, and the absence of that number cannot prove a package is genuine.
A pharmacist and manufacturer can consider multiple attributes and distribution records. Avoid broad statements such as “every item from this lot is fake,” which can wrongly implicate genuine medication.
FDA recommends that pharmacies acquire authentic Ozempic through authorized distributors and inspect supplied units. Purchases from individual resellers, anonymous social accounts or product exchange groups do not provide the same accountability as an established prescription supply chain.
Even when a physical pharmacy is licensed, a suspected item warrants direct review. The local pharmacy guide explains how to confirm the dispensing location and responsible pharmacist.
FDA previously identified counterfeit pen components and counterfeit needles in its Ozempic investigations. The potential concern is not limited to whether a medicine contains semaglutide; sterility, injection-device performance, labeling and contamination also matter.
Do not try to repair, sterilize or reuse suspicious disposable components. Have the dispensing pharmacist assess the full package and instructions supplied for the exact prescribed presentation.
A legitimate injection pen can be damaged by improper handling or shipment even when it is not counterfeit. Follow the label-specific storage requirements and ask the pharmacy to evaluate suspected temperature excursions, cracked packaging or seal damage.
See delivery and handling checks for fulfillment considerations. There is no universal rule that a product is usable based solely on how cold the package feels to the touch.
FDA provides channels for reporting suspected criminal counterfeit activity, unsafe drug sales and adverse events through MedWatch. Keep the packaging, purchase record, screenshots of the relevant offer and communications with the seller so the report can be assessed.
A suspected incident should be reported as a suspicion unless confirmed by an appropriate investigation. Consumers should not publicly accuse a named pharmacy solely on the basis of an unverified photograph or unusual appearance.
Discuss the situation with the dispensing pharmacist and prescriber before attempting replacement. Whether a new unit can be dispensed, whether a prescription remains valid and how insurance handles another claim depend on the product, circumstances and payer.
The general lawful steps are described at buying FDA-approved semaglutide legally. Never compensate for a suspect or missed dose by making an unsupervised dosing change.
Ozempic and Wegovy are prescription products with specific FDA-approved formulations. A lookalike label is not equivalent to an FDA approval, and a genuine foreign brand is not necessarily authorized for the U.S. market.
Use the FDA-approved semaglutide directory when you need to identify the current authorized U.S. products rather than evaluate one suspicious unit.
This independent guide explains product and purchasing questions but is not a pharmacy, prescriber, insurer, product-authentication laboratory or real-time inventory service. Some outbound commercial links elsewhere on this website may be affiliate or sponsored referrals, and the site may receive compensation when readers use them. Such relationships are disclosed alongside the relevant outbound link; compensation does not validate a seller or guarantee a prescription. Regulatory information was checked against FDA and other named official guidance on October 18, 2026; verify current requirements before acting.
FDA counterfeit Ozempic notices dated April 14 and December 5, 2025 were reviewed for this page on October 18, 2026. The examples are not exhaustive; current alerts and individual product investigations should be checked independently before drawing a conclusion.
No. FDA has described counterfeit products using a lot number also found on authentic units. Product identity requires more than one printed code.
No. FDA has warned that the relevant lot may also include genuine medication. Follow the exact current alert and seek pharmacist verification.
Do not use the suspected unit. Retain the carton and purchase information and contact the dispensing pharmacist for evaluation.
Counterfeit medicines have appeared in the legitimate supply chain, so pharmacy licensure reduces risk but cannot replace product investigation when concerns arise.
No. Compounding and counterfeiting are different legal and quality questions. Compounded medicines are not FDA-approved products.
No. Packaging images alone cannot establish supply-chain history, contents, device integrity or FDA approval.
Yes. Improper storage, damage or another quality problem can affect a product even when its identity is authentic.
FDA has channels for suspected drug crime, unsafe online sellers and adverse events. The dispensing pharmacy and manufacturer may also need notification.
Do not change or repeat dosing on your own. Contact the prescriber or pharmacist promptly for individualized instructions.